$ANIP News
Last published 6d ago
- 6d agoANIPANI PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 6d agoANIPANI Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswireQuarterly net revenues of $290.8 million, an increase of 27.6% year-over-yearPurified Cortrophin® Gel net revenues of $138.7 million, an increase of 36.1% year-over-yearQuarterly GAAP net income available to common
- 6d agoANIPREPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessGlobeNewswireEgetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1
- 1w agoANIPANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessGlobeNewswireEgetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1
- 1w agoANIPANI Pharmaceuticals to Present at Upcoming November Investor ConferencesGlobeNewswirePRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the
- 2w agoANIPANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETGlobeNewswirePRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday,
- 3w agoANIPANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release CapsulesGlobeNewswirePRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine
- 1mo agoANIPANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual MeetingGlobeNewswireTrial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a
- 2mo agoANIPANI Pharmaceuticals to Present at September Investor ConferencesGlobeNewswirePRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the
- 2mo agoANIPANI Pharmaceuticals Appoints Henry Gosebruch to Board of DirectorsGlobeNewswire– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP)
- 3mo agoANIPANI Pharmaceuticals Reports Record Second Quarter 2026 Financial ResultsGlobeNewswireQuarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common
- 3mo agoANIPANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETGlobeNewswirePRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August
- 3mo agoSDZ-CHHIK-GBHIK-AEFME-DE+5Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyCNBCTrump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.
- 3mo agoANIPANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology MatterGlobeNewswireTrial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the
- 4mo agoANIPANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitisGlobeNewswireTrial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported were consistent
- 5mo agoANIPANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswirePRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the
- 6mo agoANIPANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial GuidanceGlobeNewswireQuarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available to common
- 6mo agoANIPANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ETGlobeNewswirePRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8,
- 6mo agoANIPANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT ExclusivityGlobeNewswirePRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic
- 7mo agoANIPANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release CapsulesGlobeNewswirePRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's
- 7mo agoANIPANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate TabletGlobeNewswirePRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its
- 7mo agoANIPANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in OphthalmologyGlobeNewswirePRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN®
- 8mo agoANIPANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial GuidanceGlobeNewswireRecord quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6
- 8mo agoANIPANI Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the
- 9mo agoANIPANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ETGlobeNewswirePRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on
- 10mo agoANIPANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic PrioritiesGlobeNewswireFor full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37
- 10mo agoANIPANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswirePRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P.
- 11mo agoANIPANI Pharmaceuticals Announces Formation of "FutureVision Advisory Council" to Help Strategically Guide Ophthalmology and Retina FranchiseGlobeNewswirePRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic
- 11mo agoANIPANI Pharmaceuticals Announces Board TransitionGlobeNewswirePatrick D. Walsh steps down as Chairman and will complete his current term as Board memberThomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board PRINCETON, N.J., Dec. 01, 2025
- 11mo agoANIPANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswirePRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the
- 1y agoANIPANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – LondonGlobeNewswirePRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the
- 1y agoANIPANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 GuidanceGlobeNewswireRecord quarterly net revenues of $227.8 million, an increase of 53.6% year-over-yearPurified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-yearRecord quarterly adjusted non-GAAP
- 1y agoANIPANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ETGlobeNewswirePRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November
- 1y agoANIPANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 MeetingGlobeNewswirePRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide
- 1y agoANIPANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoANIPANI Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the
- 1y agoANIPANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoANIPANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 GuidanceGlobeNewswireGenerated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of $104.0 million, which
- 1y agoANIPANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ETGlobeNewswirePRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday,
- 1y agoANIPCGONDelaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI PharmaceuticalsGlobeNewswireIRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
- 1y agoANIPANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)GlobeNewswireTrial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented
- 1y agoANIPANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8thGlobeNewswirePRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at
- 1y agoANIPANI Pharmaceuticals Announces Presentation of New Preclinical DataGlobeNewswirePRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin
- 1y agoANIPANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswirePRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global
- 1y agoANIPANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout FlaresGlobeNewswirePurified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and
- 1y agoANIPANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQGlobeNewswirePRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer,
- 1y agoANIPANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 GuidanceGlobeNewswireGenerated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues
- 1y agoANIPANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse ModelGlobeNewswireDemonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) --
- 1y agoANIPANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ETGlobeNewswirePRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May
- 1y agoANIPANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual ConferenceGlobeNewswirePRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat